Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulus Hit As Partner Sanofi Pulls Plug On Kidney Drug Study

Rare Kidney Diseases Proving Difficult For Both Companies

Executive Summary

Sanofi has abandoned its study of lademirsen in Alport disease, but has not given up on the drug just yet as another indication remains in play.

You may also be interested in...



Sanofi Suffers Second Clinical Setback For Venglustat

The French drugmaker has halted a pivotal trial of venglustat in autosomal dominant polycystic kidney disease, a few months after the drug failed as a treatment for Parkinson’s disease. Sanofi will go back to focusing on the therapy's potential in lysosomal storage diseases.

Merck KGaA Overcomes Ukraine Disruption To Keep MS Frontrunner On Track

The German group is optimistic evobrutinib can be a blockbuster in multiple sclerosis and has adapted its pivotal trial to cope with disruption caused by the war in Ukraine.

GSK’s Jemperli In Search Of Lung Cancer Foothold And TIM-3 Combo Could Be Best Chance

The company wants to break into non-small cell lung cancer therapy but is unlikely to score a true hit in its head-to-head with Merck & Co’s blockbuster Keytruda.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel